Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug–Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine | Zendy

Kristina M. Brooks | Zendy; Jomy George | Zendy; Alice K. Pau | Zendy; Adam Rupert | Zendy; Carolina Mehaffy | Zendy; Prithwiraj De | Zendy; Karen M. Dobos | Zendy; Anela Kellogg | Zendy; Mary McLaughlin | Zendy; Maryellen McManus | Zendy; Raul M. Alfaro | Zendy; Colleen Hadigan | Zendy; Joseph A. Kovacs | Zendy; Parag Kumar | Zendy

Open Access

Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug–Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine

Author(s) -

Kristina M. Brooks,

Jomy George,

Alice K. Pau,

Adam Rupert,

Carolina Mehaffy,

Prithwiraj De,

Karen M. Dobos,

Anela Kellogg,

Mary McLaughlin,

Maryellen McManus,

Raul M. Alfaro,

Colleen Hadigan,

Joseph A. Kovacs,

Parag Kumar

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy082

Subject(s) - rifapentine , medicine , drug , dolutegravir , isoniazid , pharmacology , adverse effect , drug interaction , latent tuberculosis , immunology , tuberculosis , pathology , mycobacterium tuberculosis , antiretroviral therapy , viral load , human immunodeficiency virus (hiv)

Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection. This study aimed to examine pharmacokinetic drug-drug interactions between this regimen and dolutegravir, a first-line antiretroviral medication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research